Discovery of Highly Potent and Selective IKZF2 Degraders for Cancer Immunotherapy
Authors:
- 7 April 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (8) , 9615-9634
Abstract
Immunosuppressive Tregs, regulated by IKZF2, facilitate tumor immune evasion and resistance to immune checkpoint therapies. Targeted IKZF2 degradation represents a promising strategy for the development of innovative cancer immunotherapeutics. Herein, we designed and synthesized a novel series of phthalazinone-based glutarimide derivatives, identifying compound 25 as a potent, highly selective, and rapid-acting IKZF2 molecular glue degrader. Compound 25 induced robust IKZF2 degradation (DC50 = 1.78 nM and Dmax = 93.2%) via a Cullin-CRBN-dependent pathway, while sparing other CRBN neosubstrates and outperforming the benchmark degrader DKY709. Mechanistically, 25-induced IKZF2 deletion enhanced the proinflammatory IL-2 production and attenuated the immunosuppressive function of Tregs. Oral administration of 25 triggered rapid, profound, and sustained IKZF2 degradation in mice spleen and thymus. As monotherapy, 25 significantly suppressed B16F tumor growth, and 25 combined with anti-PD-1 antibody therapy exhibited marked synergistic effects. Together, our findings demonstrate 25 as a promising IKZF2 degrader for advancing cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82404417)
This publication has 35 references indexed in Scilit:
- Design and Development of IKZF2 and CK1α Dual DegradersJournal of Medicinal Chemistry, 2023
- Shining light on reprogramming Tregs for cancer therapyCell Chemical Biology, 2023
- Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapyCell Chemical Biology, 2023
- Targeting Undruggable Transcription Factors with PROTACs: Advances and PerspectivesJournal of Medicinal Chemistry, 2022
- Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesCancer Cell, 2019
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T CellsCell, 2016
- The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunityMolecular Immunology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitorsCurrent Biology, 1998